Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2003, for eXegenics Inc. (Note: The request metadata listed "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). eXegenics is an emerging pharmaceutical company focused on acquiring and developing late-stage drug candidates rather than conducting pure discovery research. During this quarter, the company executed a strategic redirection, terminating scientific programs related to OASIS and Quantum Core Technology (QCT) to reduce costs and realign priorities.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Revenue | $13,000 | $333,000 |
| Net Loss | $(987,000) | $(1,769,000) |
| Net Loss Attributable to Common Shareholders | $(1,018,000) | $(1,938,000) |
| Loss Per Share (Basic & Diluted) | $(0.07) | $(0.12) |
| Cash and Cash Equivalents (End of Period) | $14,926,000 | $14,300,000 |
| Net Cash Used in Operating Activities | $(1,236,000) | $(1,345,000) |
| Total Assets | $15,947,000 | $17,515,000 |
| Total Liabilities | $860,000 | $1,441,000 |
Liquidity: The company held approximately $15.5 million in cash and cash equivalents (including restricted cash) as of March 31, 2003. Management believes this is sufficient to fund operations through December 31, 2003.
Material Changes Versus Prior Period
- Revenue Decline: Revenue dropped 96% to $13,000 from $333,000. This was due to the non-renewal of licensing agreements with Bristol-Myers Squibb (2002) and a minimal agreement with Aventis (2003).
- Expense Reduction:
- R&D Expenses: Decreased 90% to $122,000 from $1,241,000, driven by the termination of scientific programs and reduced personnel costs.
- G&A Expenses: Decreased 24% to $805,000 from $1,061,000, primarily due to lower legal fees and facility costs.
- Strategic Redirection Costs: The company incurred $148,000 in new expenses related to severance and legal fees for terminated programs, offset by the utilization of previously accrued restructuring reserves.
- Investment Maturity: A $10,000,000 government agency debt security matured in February 2003, significantly boosting cash balances from investing activities.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management is winding down drug discovery research to focus on acquiring late-stage compounds. The wind-down of redirection expenses is expected to be substantially complete by the second quarter of 2003.
- Capital Needs: While current cash reserves are sufficient through year-end 2003, the company anticipates needing additional financing to complete new programs prior to commercialization. There is no assurance that future financing will be available on acceptable terms.
- Listing Status Risk: The company was transferred to the Nasdaq SmallCap Market in October 2002 for failing to meet the $1.00 minimum bid price. It received a 180-day extension until July 21, 2003. To avoid delisting, the stock must trade at or above $1.00 for ten consecutive trading days during an additional compliance period.
- Market Risk: The company has minimal exposure to interest rate changes or foreign currency fluctuations, as operations are U.S.-based and investments are in high-quality government obligations.
Investor Verification Checklist
- Cash Runway: Verify if the $15.5 million cash balance is sufficient to cover the burn rate through December 2003 given the new strategic direction.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 threshold required to maintain Nasdaq SmallCap listing status by July 2003.
- Revenue Pipeline: Assess the status of new licensing or acquisition deals, as current revenue streams from Aventis and Bristol-Myers Squibb are not continuing.
- Restructuring Completion: Confirm that the wind-down of terminated programs (OASIS and QCT) is proceeding as planned without unexpected additional liabilities.